Gonadorelin is simply the body's own reproductive "start" hormone, made in a lab. Its natural counterpart is GnRH — gonadotropin-releasing hormone — the signal the brain sends to the pituitary to keep the reproductive system running. Because it is GnRH itself rather than a modified copy, gonadorelin behaves exactly like the real thing, including one property that makes it unusual: whether it switches the system on or off depends entirely on timing.
In plain terms: it is natural GnRH, and it is short-acting on purpose.
What it is
Gonadorelin is a decapeptide — a chain of ten amino acids — identical to human GnRH2. GnRH is released by the hypothalamus (a control centre at the base of the brain) and travels a very short distance to the pituitary gland, where it does its whole job. Its structure was worked out in the early 1970s, a discovery important enough to earn a share of a Nobel Prize.
Being an exact copy of the natural hormone is what sets gonadorelin apart from the many GnRH agonists and antagonists (drugs like leuprolide) that are engineered to be longer-lasting. Those are altered on purpose to stay in the body. Gonadorelin is not — it comes and goes in minutes, like the hormone it copies.
How it works — and why timing is everything
Gonadorelin binds the GnRH receptor on the gonadotroph cells of the pituitary. When it does, those cells release two hormones into the blood: LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH then tells the testes to make testosterone, or triggers ovulation in the ovaries; FSH supports sperm and egg development2.
The twist is that the pattern of signalling decides the outcome. This is one of the most elegant findings in reproductive science, and it comes from a 1978 study in monkeys1:
| GnRH delivery pattern | What happens | Why |
|---|---|---|
| Pulses (about one per hour) | LH and FSH stay switched on | The receptor is designed to be poked, then rest |
| Continuous, steady exposure | LH and FSH fall — the axis shuts down | Constant signalling downregulates the receptor (desensitisation) |
In that experiment, monkeys whose own GnRH had been removed regained normal gonadotropin release only when GnRH was given in hourly pulses; giving the same hormone continuously actually suppressed the system1. This is why long-acting GnRH agonists are used to lower sex hormones (in prostate cancer, for example): flood the receptor constantly and it goes quiet.
In plain terms: the pituitary listens to rhythm, not volume. Tap it and it responds; lean on it and it stops listening.
Pharmacokinetics — minutes, not hours
Gonadorelin is cleared from the blood extremely fast. Its distribution half-life is roughly 2 to 10 minutes, and its terminal half-life is about 10 to 40 minutes2. Half-life means the time for half of a dose to clear; these are among the shortest of any peptide discussed in this space.
That short action is not a flaw — it is the point. A hormone meant to arrive in hourly pulses has to disappear quickly between pulses, or those pulses would blur into the continuous exposure that shuts the system down.
The TRT-adjunct angle
Here is where gonadorelin has found modern use. When someone takes testosterone (TRT, testosterone replacement therapy), the brain senses plenty of testosterone and stops sending its own GnRH. The pituitary then stops releasing LH, and the testes — no longer signalled — become idle, which can shrink them and reduce fertility.
The idea behind using gonadorelin as an adjunct is to supply the missing GnRH signal, keeping LH and FSH release going so the testes stay stimulated during testosterone therapy. Because gonadorelin is short-acting, it delivers a pulse-like signal rather than a constant one, at least in principle1. This is a description of the rationale and how it is studied — not a protocol, and not medical advice. It is worth noting this use is off-label.
What the evidence and history show
Note the model or source in each row:
| Milestone | Model / level | Key point | Year |
|---|---|---|---|
| Belchetz et al.1 | Rhesus monkey | Pulsatile GnRH sustains gonadotropins; continuous exposure suppresses them | 1978 |
| Factrel approval3 | Human (regulatory) | Gonadorelin gained FDA approval as a diagnostic to test pituitary function | 1982 |
| Endotext physiology review2 | Human review | Consolidates GnRH pharmacology, pulsatility and clinical use | 2024 |
The pulsatility principle has also underpinned a real therapy: pulsatile GnRH pumps have been used to restore fertility in people whose hypothalamus does not produce GnRH, precisely by mimicking the natural hourly rhythm2.
Honest limitations
Gonadorelin rests on decades of solid reproductive-endocrine science, so the biology is not in doubt12. The honest caveats are about status and use. Its once-approved diagnostic product, Factrel, was withdrawn from the US market for commercial reasons, so there is no current FDA-approved gonadorelin therapy3. Its use alongside testosterone is off-label and typically via compounding pharmacies, and controlled trials specifically testing that adjunct use are limited. Its very short half-life makes the timing of any signal central to whether it stimulates or suppresses. This page is educational, describes what studies and labels report, and takes no position on sourcing.
Latest research
- The 1978 pulsatility discovery remains foundational and still explains why the same molecule can either switch the axis on or off depending on how it arrives1.
- Interest as a TRT adjunct has grown in recent years, largely displacing older options in some clinics, but rests more on physiological rationale and compounding practice than on large dedicated trials2.
- Regulatory status is the moving part: with Factrel withdrawn, current use runs through compounding, and that landscape can shift3. We update this section as it does.
The short version
Gonadorelin is a synthetic copy of GnRH, the hormone that tells the pituitary to release LH and FSH. It is very short-acting, and its effect flips with timing: pulses stimulate the reproductive axis, constant exposure suppresses it. That makes it a rationale-driven TRT adjunct, meant to keep the testes signalled during testosterone therapy. It once held FDA approval as a diagnostic (Factrel, since withdrawn) and is now used off-label via compounding. Educational overview only, not medical advice. See also hCG and kisspeptin-10.